Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482571 | 1.00 | EGFR (0.50) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL3482568 | 1.00 | EGFR (0.50) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1191706 | 0.91 | EGFR (0.52) | EGFRERBB2ERBB4 | |
| SCHEMBL1191708 | 0.91 | EGFR (0.52) | EGFRERBB2ERBB4 | |
| SCHEMBL1191710 | 0.91 | EGFR (0.52) | EGFRERBB2ERBB4 | |
| SCHEMBL229679 | 0.90 | EGFR (0.54) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL29623524 | 0.90 | EGFR (0.54) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL229680 | 0.90 | EGFR (0.54) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL225220 | 0.90 | EGFR (0.54) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL2782327 | 0.88 | EGFR (0.54) | EGFRERBB2JAK3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586608-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-RE43431-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-7019012-B2 | Tyrosine inhibitors; antitumor agents; respiratory system disorders | BOEHRINGER INGELHEIM INTERNATIONAL PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885JAK3 45/4885 |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, RET, ABL1 | EGFR 200/4885ERBB2 122/4885JAK3 10/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | EGFR 218/4885ERBB2 109/4885JAK3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.